The use of the weight-loss drug Wegovy among U.S. adolescents increased by 50% in 2024, rising to 14.8 prescriptions per 100,000 teens, up from 9.9 in 2023, with figures reaching 17.3 in early 2025. Despite this growth, the numbers remain small compared to the 23,000 per 100,000 teens with obesity. Wegovy, approved for adolescents aged 12 and older since late 2022, offers an additional tool when lifestyle changes alone are insufficient. Truveta's analysis, based on 1.3 million teen health records, shows cautious adoption amid growing support from families and doctors. However, concerns remain due to limited long-term safety data, potential side effects like muscle loss, and minimal insurance coverage for obesity treatments.
Critics, including U.S. Health Secretary Robert F. Kennedy Jr., warn of overmedicalizing children. Some clinics, such as Nemours Children’s Hospital, reported successful weight loss with Wegovy, averaging 15 to 30 pounds over a year. Yet, many youth remain untreated due to cost, parental concerns, or unapproved alternatives. Experts emphasize the need for more data, doctor training, and comprehensive support systems to ensure informed and safe use among adolescents.
The increasing use of Wegovy among teens highlights the growing demand for effective obesity treatments in this age group. While the drug offers promising results, it's essential to balance its benefits with potential risks. Healthcare providers should carefully assess each patient's needs and monitor treatment outcomes closely. Additionally, policymakers and insurers should consider expanding coverage for obesity treatments to improve access for adolescents in need.